Cancer drug development in Europe: a selection of new agents under development at the European Drug Development Network.
From may 99, three european leaders in anti-cancer drug development (EORTC, Cancer Research UK, SENDO) have got together to form a network of collaborating groups: the European Drug Development Network. The member organisations have all agreed to join their efforts in developing new drugs. They have acquired a great and efficient expertise in anticancer drug development covering all aspects from drug screening to refinement of trial methodology and translational research. In this paper, the most interesting drugs under development in each of the three organisations are being described and discussed.
Lacombe
D
D
European Organisation for Research and Treatment of Cancer, Assistant Director/New Drug Development Program, Avenue E. Mounier, 83-b11, 1200 Brussels, Belgium. dla@eortc.be
Butler-Smith
A
A
Therasse
P
P
Fumoleau
P
P
Burtles
S
S
Calvert
H
H
Marsoni
S
S
Sessa
C
C
Verweij
J
J
D020533:Angiogenesis Inhibitors / Q000302:isolation & purification / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000302:isolation & purification / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000145:classification / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004260:DNA Repair / Q000187:drug effects; D015195:Drug Design; D004341:Drug Evaluation; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor; D004791:Enzyme Inhibitors / Q000302:isolation & purification / Q000627:therapeutic use; D005060:Europe; D006801:Humans; D007390:International Agencies / Q000458:organization & administration*; D008495:Medical Oncology / Q000458:organization & administration*; D009363:Neoplasm Proteins / Q000187:drug effects; D012106:Research / Q000458:organization & administration*; D012270:Ribosomes / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D004791:Enzyme Inhibitors; D009363:Neoplasm Proteins